1. patients with uncontrolled lymphoproliferative diseases, unresponsive aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled bleeding and coagulation diseases, etc; 2. people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); 3. patients suffering from acute disease, or acute attack of chronic disease, or uncontrolled severe chronic disease; 4. previous history of severe allergy to any vaccine or any component of the test vaccine, including aluminum preparation, such as anaphylactic shock, allergic laryngeal edema, henoch schonlein purpura, thrombocytopenic purpura, dyspnea, angioneuroedema, etc; 5. the researchers believe that the subject has any disease or condition that may put the subject at unacceptable risk; the subjects could not meet the protocol requirements; interference with the evaluation of vaccine response.

1. patients with uncontrolled lymphoproliferative diseases, unresponsive aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled bleeding and coagulation diseases, etc; 2. people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); 3. patients suffering from acute disease, or acute attack of chronic disease, or uncontrolled severe chronic disease; 4. previous history of severe allergy to any vaccine or any component of the test vaccine, including aluminum preparation, such as anaphylactic shock, allergic laryngeal edema, henoch schonlein purpura, thrombocytopenic purpura, dyspnea, angioneuroedema, etc; 5. the researchers believe that the subject has any disease or condition that may put the subject at unacceptable risk; the subjects could not meet the protocol requirements; interference with the evaluation of vaccine response.

patients with uncontrolled lymphoproliferative diseases, unresponsive aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled bleeding and coagulation diseases, etc; people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); patients suffering from acute disease, or acute attack of chronic disease, or uncontrolled severe chronic disease; previous history of severe allergy to any vaccine or any component of the test vaccine, including aluminum preparation, such as anaphylactic shock, allergic laryngeal edema, henoch schonlein purpura, thrombocytopenic purpura, dyspnea, angioneuroedema, etc; the researchers believe that the subject has any disease or condition that may put the subject at unacceptable risk; the subjects could not meet the protocol requirements; interference with the evaluation of vaccine response.

patients with uncontrolled lymphoproliferative diseases, unresponsive aplastic anemia, active primary immune thrombocytopenia (itp), uncontrolled bleeding and coagulation diseases, etc; people with uncontrolled epilepsy and other serious neurological diseases (such as transverse myelitis, guillain barre syndrome, demyelinating disease, etc.); patients suffering from acute disease, or acute attack of chronic disease, or uncontrolled severe chronic disease; previous history of severe allergy to any vaccine or any component of the test vaccine, including aluminum preparation, such as anaphylactic shock, allergic laryngeal edema, henoch schonlein purpura, thrombocytopenic purpura, dyspnea, angioneuroedema, etc; the researchers believe that the subject has any disease or condition that may put the subject at unacceptable risk; the subjects could not meet the protocol requirements; interference with the evaluation of vaccine response.